Divi's Laboratories

Divi's Laboratories EBIT

The EBIT of Divi's Laboratories (DIVISLAB.NS) as of Oct 10, 2026 is 25.70 B INR. In the previous year, EBIT was 18.31 B INR — a change of 40.36% (higher).

EBIT

25.70 BINR

YoY

40.36%

Last updated:

In 2025, Divi's Laboratories's EBIT was 25.70 B INR, a 40.36% increase from the 18.31 B INR EBIT recorded in the previous year.

The Divi's Laboratories EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
20.26 B INR
Jan 1, 2024
18.31 B INR
Jan 1, 2025
25.70 B INR
Jan 1, 2026 (e)
33.82 B INR
Jan 1, 2027 (e)
42.87 B INR
Jan 1, 2028 (e)
52.37 B INR
Jan 1, 2029 (e)
65.35 B INR
Jan 1, 2030 (e)
0.00 INR
The Divi's Laboratories EBIT history
YEAREBITYoY
est0.00INR-100.00%
est65.35 BINR+24.79%
est52.37 BINR+22.15%
est42.87 BINR+26.78%
est33.82 BINR+31.59%
25.70 BINR+40.36%
18.31 BINR-9.61%
20.26 BINR-43.30%
35.72 BINR+36.63%
26.15 BINR+59.41%
16.40 BINR-3.83%
17.06 BINR+51.54%
11.25 BINR-17.42%
13.63 BINR+4.55%
13.04 BINR+25.71%
10.37 BINR+11.70%
9.28 BINR+25.64%
7.39 BINR+17.42%
6.29 BINR+40.85%
4.47 BINR+25.36%
3.56 BINR-24.17%
4.70 BINR+22.24%
3.85 BINR+76.38%
2.18 BINR+116.70%
1.01 BINR—
Access this data via the Eulerpool API

Divi's Laboratories Revenue

Divi's Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
77.68 B INR
20.26 B INR
18.23 B INR
Jan 1, 2024
78.45 B INR
18.31 B INR
16.00 B INR
Jan 1, 2025
93.60 B INR
25.70 B INR
21.91 B INR
Jan 1, 2026 (e)
106.46 B INR
33.82 B INR
30.53 B INR
Jan 1, 2027 (e)
125.74 B INR
42.87 B INR
32.76 B INR
Jan 1, 2028 (e)
150.03 B INR
52.37 B INR
40.08 B INR
Jan 1, 2029 (e)
176.97 B INR
65.35 B INR
49.40 B INR
Jan 1, 2030 (e)
175.48 B INR
0.00 INR
0.00 INR

Divi's Laboratories Margins

Divi's Laboratories stock margins

The Divi's Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Divi's Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Divi's Laboratories.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
52.51 %
26.08 %
23.47 %
Jan 1, 2024
52.08 %
23.34 %
20.40 %
Jan 1, 2025
53.55 %
27.46 %
23.41 %
Jan 1, 2026 (e)
53.55 %
31.77 %
28.68 %
Jan 1, 2027 (e)
53.55 %
34.10 %
26.06 %
Jan 1, 2028 (e)
53.55 %
34.91 %
26.72 %
Jan 1, 2029 (e)
53.55 %
36.93 %
27.92 %
Jan 1, 2030 (e)
53.55 %
0.00 %
0.00 %

Divi's Laboratories Stock analysis

What does Divi's Laboratories do? Divi's Laboratories Ltd. is a pharmaceutical company based in Hyderabad, India. It was founded in 1990 and has become one of the leading manufacturers of active ingredients and formulations for the pharmaceutical industry in recent years. The company was founded by Dr. Murali Divi, who built the company on principles of quality, technology, and innovation. Divi's Laboratories now employs approximately 13,000 employees and operates production facilities in India and the USA. The company operates in various sectors, including generics, custom synthesis, research and development, and nutraceuticals. Its products are used worldwide and are approved in over 95 countries. Divi's Laboratories follows a vertically integrated supply chain model, producing high-quality active ingredients and developing its own formulations for the pharmaceutical industry. The company always relies on innovative technologies and continuous improvement of product quality. Its product range includes a wide range of active ingredients for various therapeutic areas, such as antibiotics, antidepressants, antihypertensives, antidiabetics, static lipid-lowering agents, and antipsychotics. Divi's Laboratories has state-of-the-art production facilities, strict quality controls, and advanced analytical facilities for all pharmaceutical ingredients. In addition to its active ingredients, the company is also known for its custom synthesis services, which involve the production of customer-specific active ingredients for the pharmaceutical industry. Divi's Laboratories offers a tailored service that meets the specific requirements of customers, ranging from the development of new active ingredients and formulations to the production of small or medium quantities of active ingredients. In the area of research and development, Divi's Laboratories works closely with academic institutions and other pharmaceutical companies to leverage the latest scientific knowledge and develop innovative products. The company invests a significant sum in research and development annually. In addition to active ingredients and custom synthesis services, Divi's Laboratories also offers a range of nutraceuticals. These products, such as vitamins, minerals, and other dietary supplements, are used to support a healthy lifestyle. In summary, Divi's Laboratories is an India-based pharmaceutical company specializing in the manufacture of active ingredients and formulations for the pharmaceutical industry. The company operates to the highest quality standards and relies on innovative technologies and sustainable product development. The wide product range and custom synthesis services offer customers a tailored solution for their needs. Divi's Laboratories is a leading provider of active ingredients and has made a name for itself in the pharmaceutical and nutraceutical industry due to its high quality and productivity. Divi's Laboratories is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Divi's Laboratories's EBIT

Divi's Laboratories's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Divi's Laboratories's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Divi's Laboratories's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Divi's Laboratories’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Divi's Laboratories stock

EBIT of Divi's Laboratories is 25.70 B INR in 2025.

EBIT of Divi's Laboratories changed from 18.31 B INR to 25.70 B INR, representing a 40.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Divi's Laboratories since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Divi's Laboratories historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Divi's Laboratories

All Key Metrics — Divi's Laboratories